What were Alivus Life Sciences Ltd's latest quarterly results?
Alivus Life Sciences Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +9.5% (stable)
- Revenue Growth YoY: +4.8%
- Operating Margin: 34.0% (volatile)
Alivus Life Sciences Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +21.6%Average7w Streak
In , Alivus Life Sciences Ltd (Pharmaceuticals Bulk Drugs & Formulation) is outperforming Nifty 500 with +21.6% relative strength. Fundamentals: Average. On a 7-week streak.
Alivus Life Sciences Ltd Key Facts
- PE Ratio
- 22.7x
- Market Cap
- ₹12,742 Cr
- PAT Growth YoY
- +10%
- Revenue Growth YoY
- +5%
- OPM
- 34.0%
- RS vs Nifty 500
- +21.6%
PE: Mid ExpansionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
🌐FII stake decreased 1.0% this quarter
🏛️DII accumulation — stake up 1.3%
💰Trading 34% below estimated fair value
Key Numbers
PAT Growth YoY
+10%
Stable
Revenue YoY
+5%
Stable
Operating Margin
34.0%
+400 bps YoY
PE Ratio
22.7
Current Price
₹1,038
Dividend Yield
0.48%
Fundamental Score
56/100
Average
3Y PAT CAGR
+5%
Market Cap
13.8K Cr
Valuation
Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Alivus Life Sciences Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +5% | +4% | Stable |
| PAT (Net Profit) | +10% | +5% | Stable |
| OPM | 34.0% | +400 bps | Volatile |
Other Top Pharmaceuticals Bulk Drugs & Formulation Stocks Beating Nifty 500
Frequently Asked Questions: Alivus Life Sciences Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Alivus Life Sciences Ltd's profit growing or declining?
Alivus Life Sciences Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +9.5% (latest quarter)
- PAT Growth QoQ: +15.4% (sequential)
- 3-Year PAT CAGR: +5.1%
- Trend: Stable — consistent growth pattern
What is Alivus Life Sciences Ltd's revenue growth trend?
Alivus Life Sciences Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +4.8%
- Revenue Growth QoQ: +14.5% (sequential)
- 3-Year Revenue CAGR: +4.0%
How is Alivus Life Sciences Ltd's operating margin trending?
Alivus Life Sciences Ltd's operating margin is volatile.
- Current OPM: 34.0%
- OPM Change YoY: +4.0% basis points
- OPM Change QoQ: +4.0% basis points
What is Alivus Life Sciences Ltd's 3-year profit and revenue CAGR?
Alivus Life Sciences Ltd's long-term compounding rates
- 3-Year Profit CAGR: +5.1%
- 3-Year Revenue CAGR: +4.0%
Is Alivus Life Sciences Ltd's growth accelerating or decelerating?
Alivus Life Sciences Ltd's earnings growth is stable with improving on a sequential basis.
- YoY Acceleration: -27.3% bps
- Sequential Acceleration: +8.8% bps
What is Alivus Life Sciences Ltd's trailing twelve month (TTM) performance?
Alivus Life Sciences Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹544 Cr
- TTM PAT Growth: +23.4% YoY
- TTM Revenue: ₹3,000 Cr
- TTM Revenue Growth: +10.5% YoY
- TTM Operating Margin: 31.1%
Is Alivus Life Sciences Ltd overvalued or undervalued?
Alivus Life Sciences Ltd appears undervalued based on our fair value analysis.
- Valuation Signal: Undervalued
- Current PE: 22.7x
- Price-to-Book: 4.2x
What is Alivus Life Sciences Ltd's current PE ratio?
Alivus Life Sciences Ltd's current PE ratio is 22.7x.
- Current PE: 22.7x
- Market Cap: 12.7K Cr
- Dividend Yield: 0.48%
How does Alivus Life Sciences Ltd's valuation compare to its history?
Alivus Life Sciences Ltd's current PE is 22.7x.
- Current PE: 22.7x
- Valuation Assessment: Undervalued
What is Alivus Life Sciences Ltd's price-to-book ratio?
Alivus Life Sciences Ltd's price-to-book ratio is 4.2x.
- Price-to-Book (P/B): 4.2x
- Book Value per Share: ₹246
- Current Price: ₹1038
Is Alivus Life Sciences Ltd a fundamentally strong company?
Alivus Life Sciences Ltd is rated Average with a fundamental score of 56.17/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +4.8% (10% weight)
- PAT Growth YoY: +9.5% (10% weight)
- PAT Growth QoQ: +15.4% (10% weight)
- Margins stable (10% weight)
Is Alivus Life Sciences Ltd debt free?
Alivus Life Sciences Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹60 Cr
What is Alivus Life Sciences Ltd's return on equity (ROE) and ROCE?
Alivus Life Sciences Ltd's return ratios over recent years
- FY2023: ROCE 30.0%
- FY2024: ROCE 28.0%
- FY2025: ROCE 25.0%
Is Alivus Life Sciences Ltd's cash flow positive?
Alivus Life Sciences Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹392 Cr
- Free Cash Flow (FCF): ₹-224 Cr
- CFO/PAT Ratio: 81% (strong cash conversion)
What is Alivus Life Sciences Ltd's dividend yield?
Alivus Life Sciences Ltd's current dividend yield is 0.48%.
- Dividend Yield: 0.48%
- Current Price: ₹1038
Who holds Alivus Life Sciences Ltd shares — promoters, FII, DII?
Alivus Life Sciences Ltd's shareholding pattern (Mar 2026)
- Promoters: 74.9%
- FII (Foreign): 5.3%
- DII (Domestic): 7.3%
- Public: 12.6%
Is promoter holding increasing or decreasing in Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 74.9% (Mar 2026)
- Previous Quarter: 74.9% (Dec 2025)
- Change: -0.04% (decreasing — worth monitoring)
How long has Alivus Life Sciences Ltd been outperforming Nifty 500?
Alivus Life Sciences Ltd has been outperforming Nifty 500 for 7 consecutive weeks, indicating building momentum.
Is Alivus Life Sciences Ltd a new momentum entry or an established outperformer?
Alivus Life Sciences Ltd is an established outperformer with 7 weeks of consecutive Nifty 500 outperformance.
Is Alivus Life Sciences Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Alivus Life Sciences Ltd may be worth studying
- Earnings growing at +9.5% YoY
- Valuation: appears undervalued
- Cash flow is positive — CFO ₹392 Cr
What is the investment thesis for Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd investment thesis summary:
Research Signals (Bull Case)
- Appears undervalued
What is the future outlook for Alivus Life Sciences Ltd?
Alivus Life Sciences Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Undervalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.